Clinical Trial Update: Safety and Efficacy Study of the Trifunctional Antibody Ertumaxomab to Treat Patients With Advanced or Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 safety and efficacy study of Ertumaxomab in patients with advanced or metastatic breast cancer was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Ertumaxomab (ertumaxomab)

Snippet

Sponsor: Neovii Biotech | Conditions: Breast Neoplasms, Breast Cancer | Phase 2 | Status: TERMINATED